Printer Friendly

EPITOPE REPORTS RECORD ANNUAL REVENUES, ANNOUNCES FOURTH-QUARTER RESULTS

              EPITOPE REPORTS RECORD ANNUAL REVENUES,
                 ANNOUNCES FOURTH-QUARTER RESULTS
    BEAVERTON, Ore., Nov. 15 /PRNewswire/ -- Epitope Inc. (AMEX: EPT) today reported record revenues of $3.8 million and a loss of $4.9 million (64 cents per share) for the year ended Sept. 30, 1991. These results compare to revenues of $3.6 million and a loss of $2.9 million (44 cents per share) for the prior year.
    "Our OraSure(R) oral specimen collection device accounted for 43 percent of the year's product revenues, primarily in the second and third quarters," said Adolph J. Ferro, president and chief executive officer.  He noted that fourth-quarter sales of OraSure were reduced due to an agreement with the Food and Drug Administration (FDA).  The agreement suspends shipments of the product for insurance HIV-1 testing in the United States pending approval of a premarket application.  The company recently received a response from the FDA with respect to the application and is in the process of providing the additional information requested by the agency.  The FDA has already approved export of OraSure to a number of foreign countries.
    "Research and development expenses amounted to $3.6 million for the year, a 64-percent increase related to expansion of our research efforts in the field of oral specimen-based diagnostic applications. With the addition of a greenhouse and micropropagation facility, we also accelerated research activities at Agritope, our agricultural biotechnology unit," said Ferro.  Epitope ended the fiscal year with the highest cash reserves in its history as a result of two European private placements, he added.
    Epitope Inc. is an Oregon corporation utilizing biotechnology to develop diagnostic tests for AIDS and other indications, therapeutic antimicrobial drugs and, through its agricultural unit, Agritope Inc., superior new plant varieties.
    A tabulation of results follows:
                         EPITOPE INC.
             (In thousands, except per-share data)
                                Three Months         Year
       Ended Sept. 30:         1991     1990     1991     1990
      Operating highlights:
    Revenues                $   650   $  734  $ 3,809  $ 3,562
    Net loss                 (1,834)    (415)  (4,922)  (2,904)
    Net loss per share        (0.23)   (0.06)   (0.64)   (0.44)
       Ended Sept. 30:                           1991     1990
      Working balance sheet data:
    Working capital                           $10,822  $ 4,057
    Assets                                     15,171    6,396
    Shareholders' equity                       14,319    5,681
    -0-                     11/15/91 R
    /CONTACT:  Mary Hagen of Epitope Inc., 503-641-6115; or Shari Annes of Annes Associates, 415-726-5400, for Epitope Inc./
    (EPT) CO:  Epitope Inc. ST:  Oregon IN:  MTC SU:  ERN SC-JH -- SE013 -- 1460 11/18/91 12:50 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 18, 1991
Words:407
Previous Article:DETROIT NEWSPAPER AGENCY APPOINTS JEANNINE DUVALL TELEMARKETING DIRECTOR
Next Article:PROPOSED SALE OF COMMUNITY FIRST'S ATWATER BRANCH TO YOSEMITE BANK CANCELED; BRANCH BECOMES PART OF VALLICORP MERGER AGREEMENT
Topics:


Related Articles
EPITOPE REPORTS SECOND-QUARTER RESULTS
EPITOPE REPORTS FIRST-QUARTER RESULTS
EPITOPE REPORTS FIRST QUARTER OPERATING RESULTS
EPITOPE, INC. REPORTS SECOND-QUARTER OPERATING RESULTS
EPITOPE REPORTS FISCAL 1996 FIRST QUARTER RESULTS
Epitope Announces First Quarter Operating Results
Epitope Announces Second Quarter Operating Results
/C O R R E C T I O N -- Epitope, Inc./(Correction Notice)
/C O R R E C T I O N -- Epitope, Inc./ (Credit Ratings)
Epitope Announces Second Quarter Operating Results

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters